Recent News - Partnerships Novelion Therapeutics has established partnerships with Recordati S.p.A. and Amryt Pharma plc for commercializing Juxtapid® in different regions. Leveraging these partnerships can create cross-selling opportunities and expand market reach.

Recent News - Acquisition Amryt Pharma plc acquired Novelion Therapeutics Inc., enhancing its product portfolio by integrating Aegerion Pharmaceuticals Inc.'s assets. This acquisition could lead to potential synergies and opportunities for combined sales efforts.

Recent News - Leadership Benjamin Harshbarger was appointed as interim CEO of Novelion Therapeutics, bringing a fresh perspective to the company's sales strategies. Engaging with the new leadership could open doors to novel sales approaches and growth.

Funding & Financials Novelion Therapeutics secured $50M in debt financing, providing a financial cushion to support sales initiatives and market expansion. This funding can be utilized to drive sales programs and explore new market segments.

Competitive Landscape Being in the biotechnology research industry, Novelion Therapeutics competes with companies like Mallinckrodt Pharmaceuticals and Syros Pharmaceuticals. Analyzing the strategies and offerings of competitors can help identify areas for competitive differentiation and targeted sales efforts.